Recommendations on prenatal screening and the connections to other diseases such as thyroid dysfunction

Clinical Chemistry and Laboratory Medicine

Volumn 50, Issue 7, 2012, Pages 1211-1220

  Springer, Drahomira ^a   Potlukova, Eliska ^a   Limanova, Zdenka ^a   Zima, Tomas ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Down's syndrome; Prenatal screening; Thyroid disease

Indexed keywords

ALPHA FETOPROTEIN; CHORIONIC GONADOTROPIN; DNA; ESTRIOL; FETAL DNA; INHIBIN; PREGNANCY ASSOCIATED PLASMA PROTEIN A; THYROID PEROXIDASE ANTIBODY; THYROTROPIN; THYROXINE; UNCLASSIFIED DRUG; UNCONJUGATED ESTRIOL;

AMNIOCENTESIS; CHORION VILLUS SAMPLING; CHROMOSOME ABERRATION; DISEASE ASSOCIATION; DOWN SYNDROME; EDWARDS SYNDROME; FEMALE; FETUS ECHOGRAPHY; GENETIC SCREENING; GESTATIONAL AGE; HORMONE DETERMINATION; HUMAN; HYPERTHYROIDISM; HYPOTHYROIDISM; INCIDENCE; LABORATORY TEST; MATERNAL CARE; NEURAL TUBE DEFECT; PRENATAL SCREENING; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; THYROID DISEASE;

DOWN SYNDROME; FEMALE; HUMANS; PREGNANCY; PRENATAL DIAGNOSIS; THYROID DISEASES; THYROID FUNCTION TESTS;

EID: 84867799538     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/cclm-2011-0598     Document Type: Review

References (92)

1. American College of Obstetricians and Gynecologists. ACOG Committee on Practice Bulletins. ACOG practice bulletin no. 77: screening for fetal chromosomal abnormalities. Obstet Gynecol. 2007;. 109:. 217-27.
2. NHS Fetal Anomaly Screening Programme committee. UK Department of Health. Screening for Down's syndrome: UK NSC policy recommendations 2007-2010: model of best practice. NHS Fetal Anomaly Screening Programme, 2008. Accessed 29 November. 2011. Available from:. http://fetalanomaly.screening.nhs.uk/ programmestatements.
3. Wald NJ, Kennard A, Smith D. First trimester biochemical screening for Down's syndrome. Ann Med 1994;26:23-9.
4. NICE clinical guideline 62, June 2010. Accessed 29 November,. 2011. Available from:. www.nice.org.uk/CG062.
5. Wald NJ, Hackshaw AK, George LM. Assay precision of serum alpha fetoprotein in antenatal screening for neural tube defects and Down's syndrome. J Med Screen 2000;7:74-7.
6. Glinoer D. The regulation of thyroid functions in pregnancy: pathways of endocrine adaptation from physiology to pathology. Endocr Rev 1997;18:404-33.
7. Rinaldi MD, Stagnaro-Green AS. Thyroid disease and pregnancy: degrees of knowledge. Thyroid 2007;17:747-51.
8. Van Cleve SN, Cohen WI. Part I: clinical practice guidelines for children with Down syndrome from birth to 12 years. J Pediat Health Care 2006;20:47-54.
9. Van Cleve SN, Cannon S, Cohen WI. Part II: clinical practice guidelines for adolescents and young adults with Down syndrome: 12 to 21 years. J Pediat Health Care 2006;20:198-205.
10. Morris J, Mutton D, Alberman E. Corrections to maternal agespecific live birth prevalence of Down's syndrome. J Med Screen 2005;12:202.
11. Frequency of Down syndrome per maternal age. Accessed 29 November. 2011. Available from:. http://www.ds-health.com/risk.htm.
12. Stein Z, Susser M, Guterman AV. Screening program for prevention of Down syndrome. Lancet 1973;1:305-9.
13. Ferguson-Smith MA, Yates JR. Maternal age specific rates for chromosome aberrations and factors influencing them: report of a collaborative European study on 52 965 amniocenteses. Prenat Diagn 1984;4:5-44.
14. Haddow JE, Palomaki GR, Knight GJ, Cunningham GC, Lustig LS, Boyd PA. Reducing the need for amniocentesis in women 35 years of age or older with serum markers for screening. N Engl J Med 1994;330:1114-8.
15. Merkatz IR, Nitowsky HM, Macri JN, Johnson WE. An association between low maternal serum alpha-fetoprotein and fetal chromosome abnormalities. Am J Obstet Gynecol 1984;148:886-94.
16. Spencer K, Carpenter P. Screening for Down's syndrome using serum α-fetoprotein: a retrospective study indicating caution. Br Med J (Clin Res Ed) 1985;290:1940-3.
17. Wald NJ, Cuckle HS, Densem JW, Nanchahal K, Royston P, Chard T, et al. Maternal serum screening for Down's syndrome in early pregnancy. Br Med J 1988;297:883-7.
18. Bogart MH, Pandian MR, Jones OW. Abnormal maternal serum chorionic gonadotropin levels in pregnancies with fetal chromosome abnormalities. Prenatal Diag 1987;7:623-30.
19. Canick JA, Knight GJ, Palomaki GE, Haddow JE, Cuckle HS, Wald NJ. Low second trimester serum unconjugated oestriol in pregnancies with Down's syndrome. Br J Obstet Gynaecol 1988;95:330-3.
20. Wald NJ, Cuckle HS, Densem JW, Nanchahal K, Canick JA, Haddow JE, et al. Maternal serum unconjugated oestriol as an antenatal screening test for Down's syndrome. Br J Obstet Gynaecol 1988;95:334-41.
21. Wald NJ, Stone R, Cuckle HS, Grudzinskas JG, Barkai G, Brambati B, et al. First trimester concentrations of pregnancy associated plasma protein A and placental protein 14 in Down's syndrome. Br Med J 1992;305:28.
22. Spencer K, Wood PJ, Anthony FW. Elevated levels of maternal serum inhibin immunoreactivity in second trimester pregnancies affected by Down's syndrome. Ann Clin Biochem 1993;30:219-20.
23. Benacerraf BR, Frigoletto FD Jr, Laboda LA. Sonographic diagnosis of Down syndrome in the second trimester. Am J Obstet Gynecol 1985;153:49-52.
24. Cuckle HS, Wald NJ, Lindenbaum RH. Maternal serum alphafetoprotein measurement: a screening test for Down syndrome. Lancet 1984;1:926-9.
25. Savva GM, Morris JK, Mutton DE, Alberman E. Maternal agespecific fetal loss rates in Down syndrome pregnancies. Prenatal Diag 2006;26:499-504.
26. Palomaki GE, Steinort K, Knight GJ, Haddow JE. Comparing three screening strategies for combining first-and second trimester Down syndrome markers. Obstet Gynecol 2006;107:367-75.
27. Weisz B, Rodeck CH. An update on antenatal screening for Down's syndrome and specific implications for assisted reproduction pregnancies. Hum Reprod Update 2006;12:513-8.
28. Summers AM, Langlois S, Wyatt P, Wilson RD. Prenatal screening for fetal aneuploidy. J Obstet Gynaecol Can 2007;29:146-79.
29. Nicolaides KH, Azar G, Byrne D, Mansur C, Marks K. Fetal nuchal translucency: ultrasound screening for chromosomal defects in first trimester of pregnancy. Br Med J 1992;304:867-9.
30. Szabo J, Gellen J. Nuchal fluid accumulation in trisomy-21 detected by vaginosonography in first trimester. Lancet 1990;336:1133.
31. Pandya PP, Snijders RJ, Johnson SP, De Lourdes Brizot M, Nicolaides KH. Screening for fetal trisomies by maternal age and fetal nuchal translucency thickness at 10 to 14 weeks of gestation. Br J Obstet Gynaecol 1995;102:957-62.
32. Spencer K, Coombes EJ, Mallard AS, Milford-Ward A. Free beta human choriogonadotropin in Down's syndrome screening: a multicentre study of its role compared with other biochemical markers. Ann Clin Biochem 1992;29:506-18.
33. Forest JC, Massé J, Moutquin JM. Screening for Down syndrome during first trimester: a prospective study using free beta-human chorionic gonadotropin and pregnancy-associated plasma protein A. Clin Biochem 1997;30:333-8.
34. Wald NJ, Watt HC, Hackshaw AK. Integrated screening for Down's syndrome based on tests performed during the first and second trimesters. N Engl J Med 1999;341:461-7.
35. Jaques AM, Halliday JL, Francis I, Bonacquisto L, Forbes R, Cronin A, et al. Follow up and evaluation of the Victorian first trimester combined screening programme for Down syndrome and trisomy 18. Br J Obstet Gynaecol 2007;114:812-8.
36. Falcon O, Auer M, Gerovassili A, Spencer K, Nicolaides KH. Screening for trisomy 21 by fetal tricuspid regurgitation, nuchal translucency and maternal serum free beta-hCG and PAPP-A at 11 + 0 to 13 + 6 weeks. Ultrasound Obstet Gynecol 2006;27:151-5.
37. Spencer K, Conwans NJ, Avgidou K, Nicolaides KH. First trimester ultrasound and biochemical markers of aneuploidy and the prediction of impending fetal death. Ultrasound Obstet Gynecol 2006;28:637-43.
38. Cuckle HS, Wald NJ, Thompson SG. Estimating a woman's risk of having a pregnancy associated with Down's syndrome using her age and serum alphafetoprotein. Br J Obstet Gynaecol 1987;94:387-402.
39. Wald NJ, Huttly WJ, Hackshaw AK. Antenatal screening for Down's syndrome with the quadruple test. Lancet 2003;361:835-6.
40. Van Lith JM. First trimester maternal serum human chorionic gonadotrophin as a marker for fetal chromosomal disorders. The Dutch Working Party on Prenatal Diagnosis. Prenatal Diag 1992;12:495-504.
41. Wald NJ, Rodeck C, Hackshaw AK, Walters J, Chitty L, Mackinson AM. First and second trimester antenatal screening for Down's syndrome: the results of the Serum, Urine and Ultrasound Screening Study (SURUSS). J Med Screen 2003;10:56-104.
42. Malone FD, Canick JA, Ball RH, Nyberg DA, Comstock CH, Bukowski R, et al., First-and Second trimester Evaluation of Risk (FASTER) Research Consortium. First trimester or second trimester screening, or both, for Down's syndrome. N Engl J Med 2005;353:2001-11.
43. Wald NJ, Rudnicka AR, Bestwick JP. Sequential and contingent prenatal screening for Down syndrome. Prenat Diagn 2006;26:769-77.
44. Mujezinovic F, Alfirevic Z. Procedure-related complications of amniocentesis and chorionic villous sampling: a systematic review. Obstet Gynecol 2007;110:687-94.
45. Odibo AO, Gray DL, Dicke JM, Stamilio DM, Macones GA, Crane JP. Revisiting the fetal loss rate after second trimester genetic amniocentesis: a single center's 16-year experience. Obstet Gynecol 2008;111:589-95.
46. ACOG Committee on Practice Bulletins. ACOG practice bulletin No. 77: screening for fetal chromosomal abnormalities. Obstet Gynecol 2007;109:217-27.
47. Leung WC, Lau ET, Lao TT, Tang MH. Can amnio-polymerase chain reaction alone replace conventional cytogenetic study for women with positive biochemical screening for fetal Down syndrome? Obstet Gynecol 2003;101:856-61.
48. Leung WC, Lau ET, Ngai C, Lam H, Leung KY, Lee CP, et al. A prospective study on the effect of rapid aneuploidy testing (amnio-PCR) on anxiety levels and quality of life measures in women and their partners with positive Down screening result. Fetal Diag Ther 2008;24:165-9.
49. Odibo AO, Dicke JM, Gray DL, Oberle B, Stamilio DM, Macones GA, et al. Evaluating the rate and risk factors for fetal loss after chorionic villus sampling. Obstet Gynecol 2008;112:813-9.
50. Tabor A, Vestergaard CH, Lidegaard O. Fetal loss rate after chorionic villus sampling and amniocentesis: an 11-year national registry study. Ultrasound Obstet Gynecol 2009;34:19-24.
51. Boyd PA, Devigan C, Khoshnood B, Loane M, Garne E, Dolk H. Survey of prenatal screening policies in Europe for structural malformations and chromosome anomalies, and their impact on detection and termination rates for neural tube defects and Down's syndrome. Br J Obstet Gynaecol 2008;115:689-96.
52. UK National Screening Committee. Fetal anomaly screening programme - screening for Down's syndrome: UK NSC policy recommendations 2007-2010: model of best practice. Accessed 29 November, 2011. Available from: http://www.dh.gov. uk/en/Publicationsandstatistics/Publications/index.htm.
53. EUROCAT Central Registry. Prenatal Screening Policies in Europe 2010. Accessed 29 November, 2011. Available from: http://www.eurocat.ulster.ac.uk/pdf/ Special-Report-Prenatal-Diagnosis.pdf.
54. Chiu RW, Akolekar R, Zheng YW, Leung TY, Lo D, et al. Noninvasive prenatal assessment of trisomy 21 by multiplexed maternal plasma DNA sequencing: large scale validity study. MBJ 2011;11:342.
55. Lo YM, Chiu RW. Noninvasive prenatal diagnosis of fetal chromosomal aneuploidies by maternal plasma nucleic acid analysis. Clin Chem 2008;54:461-6.
56. Sehnert AJ, Rhees B, Comstock D, De Feo E, Heilek G, Burke J, et al. Optimal detection of fetal chromosomal abnormalities by massively parallel DNA sequencing of cell-free fetal DNA from maternal blood. Clin Chem 2011;57:1042-9.
57. Ehrich M, Deciu C, Zwiefelhofer T, Tynan JA, Cagasan L, Tim R, et al. Noninvasive detection of fetal trisomy 21 by sequen cing of DNA in maternal blood: a study in a clinical setting. Am J Obstet Gynecol 2011;204:205.
58. Chen EZ, Chiu RK, Sun H, Akolekar R, Chan KC, Leung TY, et al. Noninvasive prenatal diagnosis of fetal trisomy 18 and trisomy 13 by maternal plasma DNA sequencing. PLoS One 2011;6:e21791.
59. Krassas GE, Poppe E, Glinoer D. Thyroid function and human reproductive health Endocr Rev 2010;31:702-5.
60. Abalovich M, Amino N, Barbour LA, Cobin RH, De Groot LJ, Glinoer D, et al. Management of thyroid dysfunction during pregnancy and postpartum: an Endocrine Society Clinical Practice Guideline. J Clin Endocrin Metab 2007;92:S1-47.
61. Stagnaro-Green A, Abalovich M, Alexander E, Fereidoun A, Jorge M, Roberto N, et al. Guidelines of the American Thyroid Association for the diagnosis and management of thyroid disease during pregnancy and postpartum. Thyroid 2011;21:1-45.
62. Negro R, Formoso G, Mangieri T, Pezzarossa A, Dazzi D, Hassan H. Euthyroid women with autoimmune thyroid disease undergoing the assisted reproduction technologies. The role of autoimmunity and thyroid function. J Clin Endocrin Metab 2007;91:2587-91.
63. Casey BM, Dashe JS, Wells CE, McIntire DD, Leveno KJ, Cunningham FG. Subclinical hyperthyroidism and pregnancy outcomes. Obstet Gynecol 2006;107:337-41.
64. Lazarus JH, Premawardhana LD. Screening for thyroid disease in pregnancy. J Clin Path 2005;58:449-52.
65. Premawardhana LD, Parkes AB, John R, Harris B, Lazarus JH. Thyroid peroxidase antibodies in early pregnancy: utility for prediction of postpartum thyroid dysfunction and implications for screening. Thyroid 2004;14:610-5.
66. Morreale De Escobar G, Obregon MJ, Escobar Del Rey F. Role of thyroid hormone during early brain development. Eur J Endocrinol 2004;151:U: 25-37.
67. Thangarantinam S, Tan A, Knox E, Kilby MD, Franklyn J, Coomarsamy A. Association between thyroid autoantibodies and miscarriage and preterm birth: meta-analysis of evidence. Br Med J 2011;9:342.
68. Li Y, Shan Z, Teng W, Xiaohui Y, Yushu L, Chenling F, et al. Abnormalities of maternal thyroid function during pregnancy affect neuropsychological development of their children at 25-30 months. Clin Endocrin 2010;72:825-9.
69. Negro R, Schwartz A, Gismondi R, Tinelli A, Mangieri T, Stagnaro-Green A. Increased pregnancy loss rate in thyroid antibody negative women with TSH levels between 2.5-5.0 in the first trimester of pregnancy. J Clin Endocrin Metab 2010;95:E44-8.
70. Henrichs J, Bongers-Schokking JJ, Schenk JJ, Ghassabian A, Schmidt HG, Visser TJ, et al. Maternal thyroid function during early pregnancy and cognitive functioning in early childhood: the generation R study. J Clin Endocrin Metab 2010;95:4227-34.
71. Stuckey BG, Kent GH, Ward LC, Brown SJ, Walsh JP. Post partum thyroid dysfunction and the long-term risk of hypothyroidism: results from a 12-year follow-up study of women with and without postpartum thyroid dysfunction. Clin Endocrin (Oxf) 2010;73:389-95.
72. Goodwin TM, Montoro M, Mestman JH, Pekary AE, Hershman JM. The role of chorionic gonadotropin in transient hyperthyroidism of hyperemesis gravidarum. J Clin Endoc Metab 1992;75:1333-7.
73. Yoshimura M, Hershman JM. Thyrotropic action of human chorionic gonadotropin. Thyroid 1995;5:425-34.
74. Haddow JE, Knight GJ, Palomaki GE, McClain MR, Pulkkinen AJ. The reference range and within-person variability of thyroid stimulating hormone during the first and second trimesters of pregnancy. J Med Screen 2004;11:170-4.
75. Lee RH, Spencer CA, Mestman JH, Miller EA, Petrovic I, Braverman LE, et al. Free T4 immunoassay are flawed during pregnancy. Am J Obstetr Gynecol 2009;200:260.
76. Pop VJ, Brouwers EP, Vadwer HL, Vulsma T, Van Baar AL, De Vijlder JJ. Maternal hypothyroxinemia during early pregnancy and subsequent child development: a 3-year follow up study. Clin Endocrinol 2003;59:282-8.
77. Delange F. Optimal iodine nutrition during pregnancy, lactation and the neonatal period. J Clin Endocrin Metab 2004;2:1-12.
78. Adlan MA, Premawardhana LD. Thyroid peroxidase antibody and screening for postpartum thyroid dysfunction. J Thyroid Res 2011:745135. Epub 2011 Jul. 10.
79. Negro R, Formoso G, Mangieri T, Pezzarossa A, Dazzi D, Hassan H. Levothyroxine treatment in euthyroid pregnant women with autoimmune thyroid disease: effects on obstetrical complications. J Clin Endocrin Metab 2006;91:2587-91.
80. Stricker RT, Echenard M, Eberhart R, Chevalier MC, Perez V, Quinn FA, et al. Evaluation of maternal thyroid function during pregnancy: the importance of using gestational age-specific reference intervals. Eur J Endocrinol 2007;157:509-14.
81. Lazarus JH. Screening for thyroid dysfunction in pregnancy: is it worthwhile? J Thyr Res 2011:397012. ECE2011-08-20.
82. Negro R, Schwartz A, Gismondi R, Tinelli A, Mangieri T, Stagnaro-Green A. Universal screening versus case finding for detection and treatment of thyroid hormonal dysfunction during pregnancy. J Clin Endocrin Metab 2010;95:1699-707.
83. Vaidya B, Anthony S, Bilous M, Shields B, Drury J, Hutchison S. Detection of thyroid dysfunction in early pregnancy: universal screening or targeted high risk case finding? J Clin Endocrin Metab 2007;92:203-7.
84. Springer D, Zima T, Limanova Z. Reference intervals in evaluation of maternal thyroid function during the first trimester of pregnancy. Eur J Endocrinol 2009;160:791-7.
85. Horacek J, Spitalnikova S, Dlabalova B. Universal screening detects two-times more thyroid disorders in early pregnancy than targeted high-risk case finding. Eur J Endocrinol 2010;163:645-50.
86. Chang DL, Leing AM, Braverman LE, Pearce EN. Thyroid testing during pregnancy at an academic Boston Area Medical Center. J Clin Endocrin Metab 2011;96:1452-6.
87. Marwaha RK, Chopra S, Gopalakrishnan S, Sharma B, Kanvar RS, Sastry A, et al. Establishment of reference range for thyroid hormones in normal pregnant Indian women. Br J Obstet Gynaecol 2008;115:602-6.
88. Zamrazil V, Bilek R, Cerovska J, Delange F. The elimination of iodine deficiency in the Czech Republic: the steps toward success. Thyroid 2004;14:49-56.
89. Potlukova E, Jiskra J, Telicka Z, Bartakova J, Springer D, Limanova Z. Postpartum follow-up of women positively screened for thyroid disease in pregnancy: the necessity of a better care. Poster 436. Presented at: 13th European Congress of Endocrinology; April 30 - May 4, 2011; Rotterdam, the Netherlands.
90. Potlukova E, Potluka O, Jiskra J, Limanova Z, Telicka Z, Bartakova J, et al. Is age a risk factor for hypothyroidism in pregnancy? An analysis of 5223 pregnant women. JCEM 2012. Available from: http://jcem.endojournals.org/content/ early/recent.
91. Dosiou C, Sanders GD, Araki SS, Crapo LM. Screening pregnant women for autoimmune thyroid disease: a cost-effectiveness analysis. Eur J Endocrinol 2008;158:841-51.
92. Thung SF, Funai EF, Grobman WA. The cost-effectiveness of universal screening in 22 pregnancies for subclinical hypothyroidism. Am J Obstet Gynecol 2009;200:267.